Zoetis Inc. $ZTS Stake Reduced by FNY Investment Advisers LLC

FNY Investment Advisers LLC cut its holdings in Zoetis Inc. (NYSE:ZTS) by 56.3% during the 2nd quarter, Holdings Channel.com reports. The fund owned 802 shares of the company’s stock after selling 1,035 shares during the quarter. FNY Investment Advisers LLC’s holdings in Zoetis were worth $125,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Nova Wealth Management Inc. bought a new stake in Zoetis in the first quarter worth about $25,000. 1248 Management LLC bought a new stake in Zoetis in the first quarter worth about $27,000. Saudi Central Bank bought a new stake in Zoetis in the first quarter worth about $29,000. Cornerstone Planning Group LLC raised its position in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after acquiring an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC raised its position in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Up 0.7%

NYSE:ZTS opened at $147.10 on Thursday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $189.98. The stock’s 50-day moving average is $148.47 and its two-hundred day moving average is $153.51. The stock has a market cap of $65.19 billion, a PE ratio of 25.32, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the previous year, the business posted $1.56 EPS. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is 34.42%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Argus restated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.